Matthew Pianko, MD
Hematology · Ann Arbor, MINPI 1245523778
Payments from drug & device makers
Across 418 payments — averaging $13,658 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.8M
- Janssen Research & Development, LLC$1.1M
- Bristol Myers Squibb$1M
- Regeneron$639K
- Pfizer$571K
- Trillium Therapeutics USA, LLC$220K
- plus $352K from 14 others
Across 50 payments — averaging $257.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$9K
- Pfizer$3K
- GSK$1K
- AbbVie$207
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 94 | $1,796,690 |
| Janssen Research & Development, LLC | 79 | $1,115,672 |
| Bristol Myers Squibb | 16 | $1,015,041 |
| Regeneron | 45 | $639,374 |
| Pfizer | 90 | $570,987 |
| Trillium Therapeutics USA, LLC | 26 | $219,619 |
| AstraZeneca | 2 | $159,405 |
| E.r. Squibb & Sons, L.L.C. | 17 | $68,023 |
| Sanofi US Services Inc. | 3 | $33,041 |
| Epizyme, Inc. | 4 | $32,200 |
| Janssen Scientific Affairs, LLC | 9 | $27,348 |
| Johnson & Johnson | 9 | $10,718 |
| Gilead | 10 | $10,691 |
| GSK | 2 | $5,200 |
| Sanofi | 3 | $3,444 |
| Karyopharm Therapeutics Inc. | 3 | $955 |
| Janssen Global Services, LLC | 1 | $600 |
| Astrazeneca UK Limited | 2 | $120 |
| Genentech USA, Inc. | 1 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
How this compares
$5,709,227 in reported general payments places this provider in the 95th percentile of 50 hematology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Ann Arbor
- Yasmin KarimiAnn Arbor$3M
- Dahlia SanoAnn Arbor$3M
- Sarah AnandAnn Arbor$2.5M
- Erica CampagnaroAnn Arbor$2.4M
- John MagenauAnn Arbor$2.2M
- Kristen PettitAnn Arbor$1.5M
- Charles FoucarAnn Arbor$830K
- Patrick BurkeAnn Arbor$635K
- Dale BixbyAnn Arbor$581K
- Albert QuieryAnn Arbor$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.